Serum M-spike and transplant outcome in patients with multiple myeloma

David M Dingli, Jorge M. Pacheco, Angela Dispenzieri, Suzanne R. Hayman, Shaji K Kumar, Martha Lacy, Dennis A. Gastineau, Morie Gertz

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

High dose therapy with autologous stem cell transplantation (HDT-ASCT) has prolonged survival in patients with multiple myeloma. Patients who achieve a complete response (CR) benefit the most from this form of therapy. Thus, achieving a CR is an important goal of therapy and it will be beneficial if the probability of achieving CR can be determined for any patient before transplant. Here we report that pretransplant monoclonal protein level (M-spike) was found to be an important predictor. Thus, we used knowledge of the rate of M-protein production by myeloma cells together with the clearance of the protein to estimate the pretransplant disease burden. We show that the pretransplant disease burden, based on the M-spike, is the only predictor for achieving CR. A simple function that describes this probability is presented. We also provide an estimate of the rate of tumor regrowth in patients who obtain a CR and in patients who only get a partial response with HDT-ASCT. The significant expansion of myeloma cells after HDT-ASCT is clearly evident. Clinical trials must be designed that take into account these kinetic aspects of the disease.

Original languageEnglish (US)
Pages (from-to)1035-1040
Number of pages6
JournalCancer Science
Volume98
Issue number7
DOIs
StatePublished - Jul 2007

Fingerprint

Multiple Myeloma
Transplants
Stem Cell Transplantation
Serum
Therapeutics
Proteins
Clinical Trials
Survival
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Serum M-spike and transplant outcome in patients with multiple myeloma. / Dingli, David M; Pacheco, Jorge M.; Dispenzieri, Angela; Hayman, Suzanne R.; Kumar, Shaji K; Lacy, Martha; Gastineau, Dennis A.; Gertz, Morie.

In: Cancer Science, Vol. 98, No. 7, 07.2007, p. 1035-1040.

Research output: Contribution to journalArticle

Dingli, David M ; Pacheco, Jorge M. ; Dispenzieri, Angela ; Hayman, Suzanne R. ; Kumar, Shaji K ; Lacy, Martha ; Gastineau, Dennis A. ; Gertz, Morie. / Serum M-spike and transplant outcome in patients with multiple myeloma. In: Cancer Science. 2007 ; Vol. 98, No. 7. pp. 1035-1040.
@article{52cd633c9435439d8ea9c97d44c7804d,
title = "Serum M-spike and transplant outcome in patients with multiple myeloma",
abstract = "High dose therapy with autologous stem cell transplantation (HDT-ASCT) has prolonged survival in patients with multiple myeloma. Patients who achieve a complete response (CR) benefit the most from this form of therapy. Thus, achieving a CR is an important goal of therapy and it will be beneficial if the probability of achieving CR can be determined for any patient before transplant. Here we report that pretransplant monoclonal protein level (M-spike) was found to be an important predictor. Thus, we used knowledge of the rate of M-protein production by myeloma cells together with the clearance of the protein to estimate the pretransplant disease burden. We show that the pretransplant disease burden, based on the M-spike, is the only predictor for achieving CR. A simple function that describes this probability is presented. We also provide an estimate of the rate of tumor regrowth in patients who obtain a CR and in patients who only get a partial response with HDT-ASCT. The significant expansion of myeloma cells after HDT-ASCT is clearly evident. Clinical trials must be designed that take into account these kinetic aspects of the disease.",
author = "Dingli, {David M} and Pacheco, {Jorge M.} and Angela Dispenzieri and Hayman, {Suzanne R.} and Kumar, {Shaji K} and Martha Lacy and Gastineau, {Dennis A.} and Morie Gertz",
year = "2007",
month = "7",
doi = "10.1111/j.1349-7006.2007.00499.x",
language = "English (US)",
volume = "98",
pages = "1035--1040",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Serum M-spike and transplant outcome in patients with multiple myeloma

AU - Dingli, David M

AU - Pacheco, Jorge M.

AU - Dispenzieri, Angela

AU - Hayman, Suzanne R.

AU - Kumar, Shaji K

AU - Lacy, Martha

AU - Gastineau, Dennis A.

AU - Gertz, Morie

PY - 2007/7

Y1 - 2007/7

N2 - High dose therapy with autologous stem cell transplantation (HDT-ASCT) has prolonged survival in patients with multiple myeloma. Patients who achieve a complete response (CR) benefit the most from this form of therapy. Thus, achieving a CR is an important goal of therapy and it will be beneficial if the probability of achieving CR can be determined for any patient before transplant. Here we report that pretransplant monoclonal protein level (M-spike) was found to be an important predictor. Thus, we used knowledge of the rate of M-protein production by myeloma cells together with the clearance of the protein to estimate the pretransplant disease burden. We show that the pretransplant disease burden, based on the M-spike, is the only predictor for achieving CR. A simple function that describes this probability is presented. We also provide an estimate of the rate of tumor regrowth in patients who obtain a CR and in patients who only get a partial response with HDT-ASCT. The significant expansion of myeloma cells after HDT-ASCT is clearly evident. Clinical trials must be designed that take into account these kinetic aspects of the disease.

AB - High dose therapy with autologous stem cell transplantation (HDT-ASCT) has prolonged survival in patients with multiple myeloma. Patients who achieve a complete response (CR) benefit the most from this form of therapy. Thus, achieving a CR is an important goal of therapy and it will be beneficial if the probability of achieving CR can be determined for any patient before transplant. Here we report that pretransplant monoclonal protein level (M-spike) was found to be an important predictor. Thus, we used knowledge of the rate of M-protein production by myeloma cells together with the clearance of the protein to estimate the pretransplant disease burden. We show that the pretransplant disease burden, based on the M-spike, is the only predictor for achieving CR. A simple function that describes this probability is presented. We also provide an estimate of the rate of tumor regrowth in patients who obtain a CR and in patients who only get a partial response with HDT-ASCT. The significant expansion of myeloma cells after HDT-ASCT is clearly evident. Clinical trials must be designed that take into account these kinetic aspects of the disease.

UR - http://www.scopus.com/inward/record.url?scp=34249890023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249890023&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2007.00499.x

DO - 10.1111/j.1349-7006.2007.00499.x

M3 - Article

C2 - 17488336

AN - SCOPUS:34249890023

VL - 98

SP - 1035

EP - 1040

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 7

ER -